NanoVibronix Presents UroShield Clinical Study At The University Of Michigan

5/22/24 8:36:09 AM ET

Industrial Specialties

Health Care

Get the next $NAOV alert in real time by email

NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week. The "pilot" phase of the study is the first component of the broader study.

As previously announced on November 28, 2023, the company signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial ("RCT") study of UroShield to further advance clinical evidence of the efficacy of UroShield. This link will take you to the company's previous press release.

Get the next $NAOV alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NAOV

Date	Price Target	Rating	Analyst

More analyst ratings

$NAOV
Press Releases

Fastest customizable press release news feed in the world

NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany
Signs Term Sheet for a License and Supply Agreement for Distribution of UroShield NanoVibronix, Inc., (NASDAQ:NAOV) (the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave ("SAW") Portable Ultrasonic Therapeutic Devices, today announced it has signed a non-binding term sheet for a license and supply agreement with APOGEPHA Arzneimittel GmbH ("APOGEPHA"), a German pharmaceutical company, which specializes in the development, marketing, sales and distribution of urology products and services. Pursuant to the term sheet, the Company and APOHEPHA intend to enter into a definitive agreement, pursuant to which, APOHEPHA will dist
10/9/24 8:30:00 AM ET
$NAOV
Industrial Specialties
Health Care
NanoVibronix Signs Letter of Intent with Potential New Distributor
NanoVibronix, Inc., (NASDAQ:NAOV) (the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a letter of intent with Medici Medical LTD ("Medici"), a leading distributor of medical products in the Israeli healthcare market, to explore the opportunities for distribution of the Company's UroShield device in Israel. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., commented, "Expanding distribution of our products with leading distributors is a key driver to accelerating market adoption of UroShield. Medici has established channels and is a l
9/23/24 8:30:00 AM ET
$NAOV
Industrial Specialties
Health Care
NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders
NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the second quarter financials and recent business developments. To Our Shareholders: We are committed to our strategic vision of developing, improving and commercializing our distinct and effective therapies, which we believe enable healthcare providers to treat patients in need, fill a void in the market and have the potential to increase stockholder value. We are focused on several areas tha
8/21/24 8:30:00 AM ET
$NAOV
Industrial Specialties
Health Care

$NAOV
Market Insights

Live Market Insights

NanoVibronix Presents UroShield Clinical Study At The University Of Michigan
NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week. The "pilot" phase of the study is the first component of the broader study.As previously announced on November 28, 2023, the company signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial ("RCT") study of UroShield to further advance clinical evidence of the efficacy of UroShield. This link will take you to the company's previous press rel
5/22/24 8:36:09 AM ET
$NAOV
Industrial Specialties
Health Care
NanoVibronix Q1 EPS $(0.23) Up From $(0.67) YoY, Sales $921.00K Up From $354.00K YoY
NanoVibronix (NASDAQ:NAOV) reported quarterly losses of $(0.23) per share. This is a 65.67 percent increase over losses of $(0.67) per share from the same period last year. The company reported $921.00 thousand in sales this quarter. This is a 160.17 percent increase over sales of $354.00 thousand the same period last year.
5/16/24 8:44:06 AM ET
$NAOV
Industrial Specialties
Health Care
NanoVibronix And VA Supplier CB Medical Announce Distribution Agreement For TheUroShield
NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix," or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a distribution agreement with CB Medical, LLC ("CB Medical") for the sale and distribution of the Company's UroShield.UroShield is an ultrasound-based product designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter-associated urinary tract infections (CAUTI). UroShield is also intended to decrease pain and discomfort associa
5/14/24 8:50:28 AM ET
$NAOV
Industrial Specialties
Health Care

$NAOV
Leadership Updates

Live Leadership Updates

NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today
NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on
12/15/22 4:05:00 PM ET
$NAOV
Industrial Specialties
Health Care
NanoVibronix Reports First Quarter 2022 Financial Results
Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to abate moving into the second half of 2022 Submitted a 510(k) application to the U.S. Food and Dr
5/17/22 8:30:00 AM ET
$NAOV
Industrial Specialties
Health Care
Cerro de Pasco Announces MCTO and New Chief Financial Officer
MONTREAL, April 29, 2022 /CNW Telbec/ - Cerro de Pasco Resources Inc. (CSE:CDPR) (Frankfurt: N8HP) ("CDPR" or the "Company") announces that it has applied to the Autorité des marchés financiers (Québec) (the "AMF"), as principal regulator of the Company, and expects to be granted a management cease trade order (the "MCTO") on May 2, 2022, pursuant to Policy Statement 12-203 Respecting Management Cease Trade Orders ("PS 12-203"). Under the MCTO, the Company's Chief Executive Officer (CEO), Chief Financial Officer (CFO) and directors may not trade in securities of the Company until such time as the Company files its audited consolidated financial statements, its management's discussion and ana
4/29/22 3:28:00 PM ET
$GMBL
$NAOV
Services-Misc. Amusement & Recreation
Consumer Discretionary
Industrial Specialties
Health Care

NanoVibronix Presents UroShield Clinical Study At The University Of Michigan

Chat with this insight

Recent Analyst Ratings for
$NAOV

$NAOV
Press Releases

Fastest customizable press release news feed in the world

NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany

NanoVibronix Signs Letter of Intent with Potential New Distributor

NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders

$NAOV
Market Insights

Live Market Insights